Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

March 24-25, 2017

New York, New York

Scientific Agenda

Friday, March 24, 2017

8:00 am

Welcome and introduction
Axel Grothey, MD and David H. Ilson, MD, PhD

Session I: Colorectal Cancers I

8:10 am

Pre-session survey using ARRAY

8:15 am

Update: The Impact of molecular subsets on adjuvant and advanced disease treatment
Howard Hochster, MD

8:40 am

Debate: What targeted therapy should be given to RAS/BRAF WT left sided colon cancers?
Either bevacizumab or EGFR antibodies are fine: Axel Grothey, MD
EGFR antibodies are mandatory: Eric Van Cutsem, MD, PhD

9:10 am

Debate: Is there an optimal treatment for refractory colorectal cancer?
TAS102 and regorafenib rule: Eric Van Cutsem, MD, PhD
Immunotherapy rules: Axel Grothey, MD

9:40 am

Post-session survey using ARRAY

9:45 am

Expert panel discussion

10:00 am

Break

Session II: Colorectal Cancers II

10:20 am

Pre-session survey using ARRAY

10:25 am

Update: Left versus right sided colon cancers: Biomarkers versus biology
Scott Kopetz, MD, PhD, FACP

10:55 am

Debate: Is observation without surgery reasonable for rectal cancers achieving a clinical CR?
Yes: Julio Garcia-Aguilar, MD, PhD
No: Christopher L. Hallemeier, MD

11:25 am

Debate: Is circulating tumor DNA ready to guide adjuvant therapy in colon cancer?
Yes, sign me up: Speaker invited
No, not so fast: Cathy Eng, MD

11:55 am

Update: The Role of aspirin therapy in GI cancer survivors and the general population
Speaker invited

12:20 pm

Post-session survey using ARRAY

12:25 pm

Expert panel discussion

12:40 pm

Lunch

Session III: Immunotherapy

2:10 pm

Pre-session survey using ARRAY

2:15 pm

Update: Immunotherapy in GI cancers
Speaker invited

2:40 pm

Debate: Novel targets such as HER2 are ready for prime time in colorectal cancer
Yes: Howard Hochster, MD
No, not yet: Tanios S. Bekaii-Saab, MD

3:10 pm

Challenging cases & expert panel discussion

3:30 pm

Post-session survey using ARRAY

3:35 pm

Break

Session IV: Gastrointestinal Malignancies – Emerging Concepts & Therapies

3:55 pm

Pre-session survey using ARRAY

4:00 pm

Update: Novel therapies beyond immunotherapy in GI Cancers
Scott Kopetz, MD, PhD, FACP

4:25 pm

Update: Advances in liquid biopsies
Speaker invited

4:50 pm

Update: Hereditary syndromes in GI cancer: Who should be tested and why?
Zsofia K. Stadler, MD

5:15 pm

Post-session survey using ARRAY

5:20 pm

Expert panel discussion

5:35 pm

Adjourn

Saturday, March 25, 2017

8:00 am

Welcome
Axel Grothey, MD and David H. Ilson, MD, PhD

Session V: Rare Tumors

8:05 am

Pre-session survey using ARRAY

8:10 am

Update: Management of anal cancer
Speaker invited

8:35 am

Update: Management of neuroendocrine cancers
Jonathan Strosberg, MD

9:05 am

Debate: Is there a role for surgical management of metastatic neuroendocrine cancer?
Yes: Michael A. Choti, MD
No: Jonathan Strosberg, MD

9:35 am

Post-session survey using ARRAY

9:40 am

Expert panel discussion

9:55 am

Break

Session VI: UGI cancers

10:15 am

Pre-session survey using ARRAY

10:20 am

Update: Molecular subtyping/profiling or update in HER2 targeted therapy
Yelena Y. Janjigian, MD

10:45 am

Debate: Does radiation therapy play a role in gastric cancer adjuvant therapy?
Peri-operative chemotherapy alone is the standard: David H. Ilson, MD, PhD
Post-operative radiation therapy is required: Christopher H. Crane, MD

11:15 am

Debate: Is surgery required after chemoradiotherapy for squamous cancer of the esophagus?
Yes: Yelena Y. Janjigian, MD
No: Christopher L. Hallemeier, MD

11:45 am

Post-session survey using ARRAY

11:50 am

Challenging cases and panel discussion

12:10 pm

Lunch

Session VI: Pancreatic Cancer and HCC I

1:40 pm

Pre-session survey using ARRAY

1:45 pm

Debate: at is the optimal neoadjuvant strategy in pancreatic cancer?
Chemotherapy alone: Jordan Berlin, MD
Preop chemotherapy plus radiation: Christopher H. Crane, MD

2:15 pm

Debate: What is the optimal adjuvant chemotherapy for resected pancreatic cancer?
Gemcitabine/nab-paclitaxel: Jordan Berlin, MD
Gemcitabine/capecitabine: Tanios S. Bekaii-Saab, MD

2:45 pm

Update: What is new in targeted therapy for pancreatic cancer?
Eileen O'Reilly, MD

3:10 pm

Post-session survey using ARRAY

3:15 pm

Break

Session VII: Pancreatic Cancer and HCC II

3:35 pm

Pre-session survey using ARRAY

3:40 pm

Update: Novel endoscopic management of pancreatic biliary cancers
Mark A. Schattner, MD, FACP, CNSP

4:05 pm

Debate: Is there a standard second line therapy for HCC?
Regorafenib is a winner: Ghassan Abou-Alfa, MD, MBA
There is no standard second line therapy: Tanios S. Bekaii-Saab, MD

4:35 pm

Challenging cases and panel discussion

5:00 pm

Update: Novel treatments for HCC in the era of hep C therapies
Ghassan Abou-Alfa, MD, MBA

5:25 pm

Post-session survey using ARRAY

5:30 pm

Expert panel discussion

5:45 pm

Closing notes & adjourn